About 10 million doses of the AstraZeneca vaccine have been produced but have yet to pass a review by the FDA to “meet its expectations for product quality.” About 50 million more doses are in various stages of production and could be available to ship in May and June.
The U.S. has yet to finalize where the AstraZeneca doses will go. Neighbors Mexico and Canada have asked the Biden administration to share more doses.
“We’re in the planning process at this point in time,” said White House press secretary Jen Psaki, when asked where the doses would go.
As it was reported, Emergent BioSolutions factory, which belongs to Johnson & Johnson company stopped production of AstraZeneca vaccine in the United States. This step was made in order to avoid last week's mistake; 15,000,000 doses of the vaccine were rejected as defective when workers of the factory mixed Johnson&Johnson vaccine with another drug.